Inventor · disambiguated record
Mireille Gillings
Also filed as: GILLINGS MIREILLE · GILLINGS MIREILLE G
11 granted patents·16 pending applications·28 citations·filing 2017–2025
87Inventor score
Top patents by PatentIndex Score
27 records- 0192US11020374B2Sulcardine saltsHUYA BIOSCIENCE INT LLC·Filed 2020·Granted Jun 1, 2021·4 cites·19 claims
- 0292US10385131B2Combination therapies of HDAC inhibitors and PD-L1 inhibitorsHUYA BIOSCIENCE INT LLC·Filed 2017·Granted Aug 20, 2019·9 cites·8 claims
- 0389US11813245B2Sulcardine administration for treatment of acute atrial fibrillationHUYABIO INT LLC·Filed 2021·Granted Nov 14, 2023·2 cites·45 claims
- 0489US10287353B2Combination therapies of HDAC inhibitors and PD-1 inhibitorsHUYA BIOSCIENCE INT LLC·Filed 2018·Granted May 14, 2019·9 cites·6 claims
- 0585US12097203B2Combination therapies comprising SHP2 inhibitors and PD-1 inhibitorsHUYABIO INT LLC·Filed 2022·Granted Sep 24, 2024·1 cites·31 claims
- 0683US2025026832A1Combination therapies of hdac inhibitors and pd-1 inhibitorsHUYABIO INT LLC·Filed 2024·Application pending·0 cites
- 0780US11535670B2Combination therapies of HDAC inhibitors and PD-L1 inhibitorsHUYABIO INT LLC·Filed 2019·Granted Dec 27, 2022·1 cites·12 claims
- 0878US10385130B2Combination therapies of HDAC inhibitors and PD-1 inhibitorsHUYA BIOSCIENCE INT LLC·Filed 2017·Granted Aug 20, 2019·2 cites·16 claims
- 0976US12465587B2Sulcardine administration for treatment of acute atrial fibrillationHUYABIO INT LLC·Filed 2023·Granted Nov 11, 2025·0 cites·23 claims
- 1074US12122833B2Combination therapies of HDAC inhibitors and PD-1 inhibitorsHUYABIO INT LLC·Filed 2019·Granted Oct 22, 2024·0 cites·18 claims
- 1173US2023151099A1Combination therapies of hdac inhibitors and pd-l1 inhibitorsHUYABIO INT LLC·Filed 2022·Application pending·0 cites
- 1270US2025144072A9Sulcardine saltsHUYABIO INT LLC·Filed 2022·Application pending·0 cites
- 1368US12390469B2SHP2 inhibitor monotherapy and uses thereofHUYABIO INT LLC·Filed 2022·Granted Aug 19, 2025·0 cites·26 claims
- 1468US2025367204A1Shp2 inhibitor monotherapy and uses thereofHUYABIO INT LLC·Filed 2025·Application pending·0 cites
- 1565US11426382B2Sulcardine saltsHUYABIO INT LLC·Filed 2020·Granted Aug 30, 2022·0 cites·3 claims
- 1664US2024252490A1Combination Therapies Comprising Kras Inhibitors and SPH2 InhibitorsHUYABIO INT LLC·Filed 2023·Application pending·0 cites
- 1763US2025134899A1Combination therapies of wdr5 inhibitors and pd-1 inhibitorsHUYABIO INT LLC·Filed 2024·Application pending·0 cites
- 1862US2023286948A1Haloalkylpyridyl triazole mll1-wdr5 protein-protein interaction inhibitorHUYABIO INT LLC·Filed 2023·Application pending·0 cites
- 1960US2023286925A1Phenyl triazole mll1-wdr5 protein-protein interaction inhibitorHUYABIO INT LLC·Filed 2023·Application pending·0 cites
- 2060US2025326785A1Sodium salt and ethanolamine salt of 23-hydroxytormentic acidHUYABIO INT LLC·Filed 2025·Application pending·0 cites
- 2160US2024252474A1Methods and compositions comprising a cardio-tolerated hdac inhibitorHUYABIO INT LLC·Filed 2024·Application pending·0 cites
- 2259US2023293539A1Mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereofHUYABIO INT LLC·Filed 2023·Application pending·0 cites
- 2358US2024041865A1Combination therapies of wdr-5 inhibitors and pd-1 inhibitorsHUYABIO INT LLC·Filed 2023·Application pending·0 cites
- 2455US2022370456A1Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitorsHUYABIO INT LLC·Filed 2022·Application pending·0 cites
- 2554US2022110924A1Methods and compositions for genetic modulation of tumor microenvironmentsHUYABIO INT LLC·Filed 2021·Application pending·0 cites
- 2648US2020383961A1Triplet therapies of hdac inhibitors, pd-l1 and/or pd-1 inhibitors, and ctla-4 inhibitorsHUYA BIOSCIENCE INT LLC·Filed 2020·Application pending·0 cites
- 2744US2019046513A1Combination therapies of hdac inhibitors and tubulin inhibitorsHUYA BIOSCIENCE INT LLC·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →